J&J (JNJ) Gets EU Approval for Bladder Cancer Drug Balversa

Johnson & Johnson (JNJ) announced that the European Commission has granted marketing approval to its drug Balversa (erdafitinib) for treating unresectable or metastatic urothelial carcinoma (UC), harboring susceptible FGFR3 genetic alterations.The drug has been approved for UC patients who have previously received at least one line of therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic treatment setting.UC is the most common type of bladder cancer. Europe has the highest rate of b ...